Immune cell therapy shows promise for tough autoimmune cases

NCT ID NCT06614270

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment using specially engineered immune cells (CAR-NK) from cord blood for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis that haven't responded to standard therapies. The goal is to see if it's safe and can control the disease. About 15 adults aged 18-65 will receive the cells and be monitored for side effects and symptom improvement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED VASCULITIS (AAV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anti-neutrophil cytoplasmic antibody-associated vasculitis antiphospholipid syndrome granulomatosis with polyangiitis idiopathic inflammatory myopathy myositis disease Sjogren syndrome systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANCA ASSOCIATED VASCULITIS (AAV) ANTIPHOSPHOLIPID SYNDROME IDIOPATHIC INFLAMMATORY MYOPATHY (IIM) SJOGREN'S SYNDROME SYSTEMIC LUPUS ERYTHEMATOSUS SYSTEMIC SCLEROSIS (SSC)

Contacts and locations

Locations

the second affiliated hospital Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310005, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.